register

Digital & Innovation

Purposeful innovation a must in enhancing customer experience, says AbbVie’s Strategy and Innovation leader

Health Industry Hub | October 12, 2022 |

Digital & Innovation: Through the recent years of unprecedented global disruption and uncertainty, leaders have taken their commitment to innovation to a whole new level. Organisations that prioritise growth and innovation during crises tend to leap ahead of competitors that retrench.

AbbVie ANZ’s commitment to innovation has been amplified by the company’s investment in a unique role that does not exist in most other pharma and medtech organisations.

Mahesh Malalage, Head of Strategy and Innovation at AbbVie ANZ joined Health Industry Hub to discuss how innovation has evolved, the business drivers that are leading organisations to invest in innovation and key gaps in innovation that need to be addressed in the current environment.

Mahesh reflected on how to build an organisational culture around innovation and the levers for success in the new hybrid working ecosystem. He shared what best practice looks like when thinking about purposeful innovation to enhance customer experience.


News - MedTech & Diagnostics

Hearts4heart takes aim at private system leaving patients to pay the price

Hearts4heart takes aim at health insurers leaving patients to pay the price

Health Industry Hub | September 4, 2026 |

Persistent advocacy by patient groups has prompted the Medical Services Advisory Committee (MSAC) to review the funding gaps for pulsed […]

More


News - MedTech & Diagnostics

Queensland first: Private hospital deploys Abbott's PFA in atrial fibrillation

Queensland first: Private hospitals deploy Abbott’s PFA in atrial fibrillation

Health Industry Hub | September 4, 2026 |

More Australians living with atrial fibrillation (AF) are gaining access to one of the latest advances in heart-rhythm treatment, with […]

More


News - Pharmaceuticals

Five years of HTA reform talk, Now comes the $47 billion question

Five years of HTA reform talk, now comes the $47 billion question

Health Industry Hub | September 4, 2026 |

Medicines Australia has put a $47 billion price tag on what it says Australia must invest to improve equitable access […]

More


News - Pharmaceuticals

New MFN deals raise the stakes for Australia’s delayed HTA reform

New MFN deals raise the stakes for Australia’s delayed HTA reform

Health Industry Hub | September 2, 2026 |

Four months after the US Trump administration concluded what was expected to be the final tranche of drug-pricing agreements with […]

More


This content is copyright protected. Please subscribe to gain access.